Cancer-Attributable Costs of Diagnosis and Care for Persons with Screen-Detected Versus Symptom-Detected Colorectal Cancer

Gastroenterology

Volumn 125, Issue 6, 2003, Pages 1645-1650

  Ramsey, Scott D ^a,b   Mandelson, Margaret T ^a,c   Berry, Kristin ^a   Etzioni, Ruth ^a   Harrison, Robert ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CLINICAL FEATURE; COLORECTAL CANCER; COST BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

EID: 0344628831     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.09.032     Document Type: Article

References (29)

1. U.S. Preventive Services Task Force. Screening: colorectal cancer, update, 2002 release. U.S. Preventive Services Task Force, 2002. Available at: http://www.ahrq.gov/clinic/uspstf/usps-colo.htm. Accessed April 2, 2003.
2. American Cancer Society homepage. American Cancer Society, Inc., 2003. Available at: http://www.cancer/org. Accessed April 2, 2003.
3. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473-481.
4. Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32,702 veterans. Ann Intern Med 1995;123:904-910.
5. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-1371.
6. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471.
7. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477.
8. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 1999;34:414-420.
9. Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992;84:1572-1575.
10. Selby JV, Friedman GD, Quesenberry CP Jr, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.
11. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000;284:1954-1961.
12. Vijan S, Hwang EW, Hofer TP, Hayward RA. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001;111:593-601.
13. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Intern Med 2000;133:573-584.
14. Breen N, Wagener DK, Brown ML, Davis WW, Ballard-Barbash R. Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys. J Natl Cancer Inst 2001;93:1704-1713.
15. Brown ML, Riley GF, Potosky AL, Etzioni RD. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care 1999;37:1249-1259.
16. Ramsey SD, Berry K, Etzioni R. Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. Am J Gastroenterol 2002;97:440-445.
17. Ray GT, Collin F, Lieu T, Fireman B, Colby CJ, Quesenberry CP, Van den Eeden SK, Selby JV. The cost of health conditions in a health maintenance organization. Med Care Res Rev 2000;57:92-109.
18. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-426.
19. Surveillance, Epidemiology and End Results (SEER). National Cancer Institute, 2003. Available at: http://www.seer.cancer.gov. Accessed April 2, 2003.
20. Fishman P, Von Korff M, Lozano P, Hecht J. The direct costs of chronic illness in a staff model HMO. Health Aff 1997;16:239-247.
21. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995;33:783-795.
22. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197-203.
23. Putnam KG, Buist DS, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Arnold Chan K. Chronic disease score as a predictor of hospitalization. Epidemiology 2002;13:340-346.
24. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-434.
25. Lin DY. Proportional means regression for censored medical costs. Biometrics 2000;56:775-778.
26. Fletcher RH, Colditz GA, Pawlson LG, Richman H, Rosenthal D, Salber PR. Screening for colorectal cancer: the business case. Am J Manag Care 2002;8:531-538.
27. Colorectal cancer test use among persons aged > or = 50 years-United States, 2001. MMWR Morb Mortal Wkly Rep 2003;14:193-196.
28. Hawley ST, Levin B, Vernon SW. Colorectal cancer screening by primary care physicians in two medical care organizations. Cancer Detect Prev 2001;25:309-318.
29. Schroy PC III, Geller AC, Crosier Wood M, Page M, Sutherland L, Holm LJ, Heeren T. Utilization of colorectal cancer screening tests: a 1997 survey of Massachusetts internists. Prev Med 2001;33:381-391.